IJMPR 2024, 8(6), 39-47

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 6.669

INJECTABLES IN MEDICINE: A COMPREHENSIVE REVIEW AND FUTURE PERSPECTIVES

Rompicharla Narasimha Sai, Singareddy Yasaswini*, Haranath Chinthaginjala, Lavani Firdos, Turubilli Satish and Kasi Praveena

Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - AUTONOMOUS, KR Palli Cross, Chiyyedu (Po), Anantapur -51572, Andhra Pradesh, India.

Article Received on: 10/04/2024
Article Revised on: 30/04/2024
Article Accepted on: 20/05/2024

***Corresponding Author**
Singareddy Yasaswini
Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - AUTONOMOUS, KR Palli Cross, Chiyyedu (Po), Anantapur -51572, Andhra Pradesh, India.

ABSTRACT

Injectables, a cornerstone in modern medicine, have witnessed remarkable advancements and continue to play a pivotal role in diverse therapeutic areas. This comprehensive review provides a thorough overview of injectables, encompassing their types, administration routes, and applications across various medical disciplines. The paper explores the diversity of injectable formulations, including small molecules, biologics, and gene therapies, underscoring their impact on disease management and patient outcomes. The discussion delves into the nuances of injection techniques, emphasizing the importance of proper administration, needle selection, and aseptic practices. It explores the challenges and solutions associated with injectable preparations, addressing issues such as contamination, medication errors, and patient adherence. Noteworthy technological innovations, such as biodegradable microneedle patches, smart injection devices, and continuous manufacturing processes, are highlighted for their potential to revolutionize drug delivery and enhance patient experience. Looking toward the future, the review examines the prospects of injectables in personalized medicine, precision therapeutics. It anticipates continued developments in long-acting formulations, nanoparticle-based drug delivery, and the integration of mRNA technology. The impact of injectables on global health, especially in the context of pandemics and vaccine delivery, is discussed, emphasizing the need for secure supply chains and advanced delivery systems. This review provides a holistic understanding of injectables, reflecting on their evolution, current status, and future trajectories. As the field progresses, a synergy of technological innovation, precision medicine, and improved patient engagement promises to shape the landscape of injectables, contributing significantly to advancements in healthcare.

KEYWORDS: injectables, Biologics, Aseptic practices, mRNA technology, Personalized medicine.

INTRODUCTION

Injectables, a cornerstone of modern medicine, have become indispensable in the treatment landscape, offering precision and efficacy in drug delivery across a spectrum of therapeutic interventions. This review explores the multifaceted domain of injectables, diverse formulations, administration techniques, and the transformative impact they have on healthcare.[1] The landscape of injectables spans a rich tapestry of formulations, encompassing small molecules, biologics, and nucleic acid-based therapies. The advent of biodegradable microneedles, exemplifying innovation at the intersection of materials science and drug delivery, marks a paradigm shift in painless and patient-friendly administration.[2] Smart injection devices equipped with connectivity features not only ensure accurate dosage but also herald an era of real-time monitoring, fostering a proactive approach to patient care.[3]

The future of injectables unfolds against the backdrop of personalized medicine, where tailored therapies based on individual genetic makeup promise unprecedented precision. Gene therapies, propelled by advancements in mRNA technology, are redefining treatment modalities for genetic disorders and certain cancers.[4] This comprehensive exploration aims to provide a holistic understanding of injectables, traversing historical milestones, current advancements, and the promising trajectories that lie ahead. By navigating through the intricate facets of injectables, from formulation intricacies to futuristic technologies, this review aspires to be a valuable resource for healthcare professionals, researchers, and stakeholders engaged in shaping the future of medical therapeutics.[5] The field of injectables is diverse, covering various types of drugs and formulations. There is a broad categorization of injectables based on their formulations and intended use.

Solutions, Suspensions, Emulsions, Liposomes, Depot Injections, Biologics (Monoclonal Antibodies, Vaccines), Hormones and Peptides (Insulin Injections), Anti-Coagulants and Antiplatelet Agents, Local anaesthetics, Antibiotics, Radiographic Contrast Media (Iodine), Chemotherapy Agents are some of the liquid injectables used.

STERILIZATION

Sterilization is a critical step in the manufacturing of injectables to ensure that the final product is free from viable microorganisms.

Common sterilization techniques used in the production of injectables

Autoclaving

High-pressure saturated steam at a temperature typically between 121°C to 134°C.

Filtration

Through a membrane filter with a pore size small enough to capture microorganisms (1 micron or less).[6]

Dry Heat Sterilization

Exposing the product to high temperatures in the absence of moisture.

Gamma Irradiation

Gamma irradiation uses high-energy gamma rays to kill microorganisms by damaging their DNA.[7]

Ethylene Oxide (ETO) Sterilization

Ethylene oxide is a gas that is effective at sterilizing heat- and moisture-sensitive materials.[8]

Aseptic Processing

Maintaining a sterile environment.[9]

Vaporized Hydrogen Peroxide (VHP) Sterilization

VHP is a sterilization method that utilizes hydrogen peroxide vapor to kill microorganisms.[10]

The choice of sterilization method depends on the nature of the product, the materials involved, and the intended use. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), provide guidelines for the validation and use of sterilization processes in the pharmaceutical industry. Strict adherence to these guidelines is crucial to ensuring the safety and efficacy of injectable products.

ASEPTIC TECHNIQUES

To maintain sterility during the entire process in the preparation of parenteral dosage forms. Aseptic techniques are crucial in the preparation of parenteral dosage forms to maintain sterility throughout the entire process. The key practices to ensure aseptic conditions, Cleanroom Facilities, Personal Protective Equipment (PPE), Hand Hygiene, Disinfection of Surfaces, Sterilization of Equipment, Aseptic Transfer Techniques, Personnel Training, Media Fills and Process Simulations, Quality Control Testing, Documentation and Record Keeping.[11] Aseptic techniques should be consistently practiced and validated to meet regulatory standards for the production of injectables. Regular training, audits, and continuous improvement efforts are essential components of a robust aseptic processing program. Always adhere to current Good Manufacturing practice (c GMP) guidelines and other relevant regulatory requirements.[12]

QUALITY CONTROL MEASURES COMMONLY IMPLEMENTED IN THE MANUFACTURING OF INJECTABLES

Raw Material Testing for Identification, Purity and Microbial Quality. (sentence formations)

In-Process Testing is a Sterility Testing, Endotoxin Testing.

Finished Product Testing is the testing of Appearance, Integrity, Container Closure Integrity Testing, Particle Size, Particle Count, pH, Osmolality, Assay and Content Uniformity.[13]

Stability Testing is a Long-Term and Accelerated Stability Studies. Environmental Monitoring is a Cleanroom Monitoring and Air Quality Monitoring. Validation and Qualification is a Process Validation and Analytical Method Validation.[14]

Batch Record Review, Documentation of everything involved. Quality Management System is to check the Deviation and CAPA (corrective and preventive actions) Management, Change Control system.[15]

Regulatory Compliance is to the Adherence to cGMP. Quality Control Laboratories-Qualified Personnel, Instrument Calibration and Maintenance.[16]

These quality control measures collectively contribute to the production of safe and effective injectable products.

FORMULATION AND COMPOUNDING

The formulation of injectables involves careful consideration of the active pharmaceutical ingredients (APIs) and excipients to ensure the safety, efficacy, and stability of the final product. Injectable formulations demand meticulous attention to detail, and the selection of excipients and APIs plays a crucial role in achieving the desired therapeutic outcomes. Collaboration between formulation scientists, pharmacists, and regulatory experts is essential to navigate the complexities of injectable product development.

Compounding process and the importance of accurately measuring and mixing components in injectables

The compounding process for injectables involves the accurate measurement and precise mixing of components

to create a pharmaceutical product that meets specified quality and safety standards.

An overview of the compounding process and the importance of accuracy in injectable formulations Weighing and Measuring: Precision Instruments, Dosing Accuracy.

Mixing and Dissolution: Homogeneity, Dissolution.[17]

Sterilization: Aseptic Techniques, Sterilization of Equipment.

Filtration: Particle Removal, Microbial Control.

Quality Control Testing: In-Process Testing, Final Product Testing.

Validation: Process Validation, Analytical Method Validation.[18]

Importance of Accurate Measurement and Mixing

Dosage Accuracy

Accurate measurement ensures the correct dosage of the active pharmaceutical ingredient, preventing underdosing or overdosing.

Therapeutic Efficacy

Accurate mixing guarantees the uniform distribution of components, contributing to the therapeutic efficacy of the injectable.[19]

Consistency in Quality

Accurate compounding leads to batch-to-batch consistency, essential for maintaining product quality and meeting regulatory requirements.[20]

Aseptic Assurance

Accurate aseptic techniques and precise measurement contribute to the maintenance of sterility, crucial for injectables to avoid microbial contamination.[21]

Regulatory Compliance

Adherence to accurate measurement and mixing practices is essential for compliance with Good Manufacturing Practice (GMP) regulations and other regulatory standards.[22]

Prevention of Incompatibilities

Accurate compounding minimizes the risk of incompatibilities between components, which could lead to physical or chemical instability.[23]

The compounding process for injectables demands meticulous attention to detail, accuracy in measurement, and precise mixing to ensure the production of safe, effective, and consistent pharmaceutical products.

USFDA: GUIDELINES

The U.S. Food and Drug Administration (FDA) has established specific regulatory guidelines for the production of injectable drugs to ensure the safety, efficacy, and quality of these pharmaceutical products. The primary regulatory framework for injectables falls under Current Good Manufacturing Practice (cGMP) regulations, which are outlined in Title 21 of the Code of Federal Regulations (CFR), Parts 210 and 211.[24]

Pharmaceutical manufacturers must be well-versed in the regulations and guidelines to ensure compliance during the development, manufacturing, and post-market phases of injectable drug products. Adherence to these guidelines is crucial for obtaining regulatory approval and maintaining the quality and safety of injectables in the market.

ICH GUIDELINES

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines that are recognized globally and are intended to harmonize regulatory requirements across regions. While ICH does not specifically have guidelines exclusively for injectables, several ICH guidelines are relevant to the development and manufacturing of injectable pharmaceuticals.

Important ICH guidelines that are applicable for injectables

ICH Q1 - Q14 Guidelines

ICH Q1A(R2) - Stability Testing of New Drug Substances and Products: Provides guidance on stability testing, which is crucial for determining the shelf life and storage conditions of injectables.

ICH Q2(R1) - Validation of Analytical Procedures: Offers guidance on the validation of analytical methods used for testing injectable products.

ICH Q3A(R2) - Impurities in New Drug Substances: Addresses the qualification and control of impurities, including those in injectable drug substances.

ICH Q3C(R7) - Impurities: Guideline for Residual Solvents: Provides guidance on acceptable levels of residual solvents in pharmaceuticals, including injectables.

ICH Q5A(R1) - Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin: Relevant for injectables, particularly biologics.

ICH Q5E - Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process: Addresses the assessment of comparability for biotechnological/biological products, including injectables.

ICH Q7 - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients: Focuses on GMP for active pharmaceutical ingredients, which are integral to the manufacturing of injectables.

ICH Q8(R2) - Pharmaceutical Development: Provides guidance on pharmaceutical development, including the development of injectable drug products.

ICH Q9 - Quality Risk Management: Relevant for managing quality risks throughout the lifecycle of injectable products.

ICH Q10 - Pharmaceutical Quality System: Discusses the establishment of a pharmaceutical quality system, applicable to the quality management of injectables.

ICH Q11 - Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities): Relevant for the development and manufacture of drug substances used in injectables.

ICH Q12 - Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management: Provides guidance on managing the lifecycle of pharmaceutical products, including injectables.

ICH Q13 - Continuous Manufacturing of Drug Substances and Drug Products: Addresses continuous manufacturing processes, which may be relevant to the production of injectables.[25]

These guidelines cover various aspects of pharmaceutical development, manufacturing, and quality assurance, and they can be applied to the specific challenges and requirements of injectable products. It's essential for pharmaceutical companies to consider and adhere to relevant ICH guidelines in conjunction with regional regulatory requirements when developing and manufacturing injectable pharmaceuticals.

FUTURE PROSPECTUS ABOUT THE INJECTABLES AND THEIR SCOPE IN CONTRIBUTING TO WORDS THE WORLD HEALTH

The landscape of healthcare and pharmaceuticals can evolve rapidly, and new developments may have occurred since then.

Increasing Demand for Biologics

The demand for injectable biologic drugs, including monoclonal antibodies and therapeutic proteins, is expected to rise. These drugs often require injection for effective delivery and are essential in treating various diseases, including cancer, autoimmune disorders, and infectious diseases.[26]

Innovation in Drug Delivery Systems

Ongoing innovation in drug delivery systems for injectables is likely to improve patient adherence, reduce side effects, and enhance the overall effectiveness of treatments. This includes sustained-release formulations, smart injectors, and microneedle technologies.[27]

Personalized Medicine and Precision Therapeutics

The trend toward personalized medicine is influencing the development of injectable therapies tailored to individual patient profiles. This may include personalized cancer vaccines, gene therapies, and immunotherapies.[28]

Combination Products

The development of combination products, where injectable drugs are integrated with delivery devices, is expected to grow. This can enhance convenience, dosage accuracy, and patient outcomes.

Expansion of Biosimilars

With the expiration of patents for several biologics, there is an increasing market for biosimilar injectables. This can contribute to cost savings and improved access to essential treatments.

Emergence of mRNA Vaccines and Therapies

The success of mRNA-based COVID-19 vaccines has sparked interest in the broader application of mRNA technology for other vaccines and therapies delivered through injection.[29]

Global Immunization Programs

Continued efforts in global vaccination programs are expected, addressing both infectious diseases and emerging health threats.[30]

Regulatory Environment and Quality Standards

Regulatory bodies worldwide are likely to maintain stringent quality standards for injectable pharmaceuticals to ensure patient safety and product efficacy.

Global Access and Affordability

Initiatives to improve access to essential injectable medications globally, particularly in low- and middle-income countries, will likely continue.[31]

Pandemic Preparedness

The experience of the COVID-19 pandemic has underscored the importance of injectable vaccines and therapeutics in global health security. Future developments may focus on preparedness for potential health crises.

The future of injectables in healthcare is dynamic, driven by scientific advancements, evolving healthcare needs, and the global health landscape. Continued research, innovation, and collaboration between industry, academia, and regulatory bodies will be pivotal in

shaping the role of injectables in improving health outcomes worldwide.[32]

FUTURE TECHNOLOGICAL ADVANCEMENTS IN THE INJECTABLES FOR FUTURE GENERATIONS

Anticipating future technological advancements in injectables involves considering ongoing trends in the pharmaceutical and healthcare industries. While specific developments may emerge. Some potential areas of advancement for injectable technologies are given below.

Smart Drug Delivery Systems

Injectable devices with Internet of Things (IoT) capabilities may enable real-time monitoring and data collection on patient responses to treatments, allowing for personalized and adaptive therapy adjustments.

Nanotechnology and Nanomedicine

Advancements in nanotechnology may lead to more precise and targeted drug delivery systems. Nanoparticles could be engineered to carry therapeutic agents directly to specific cells or tissues.

Gene Therapy Delivery

Injectable gene therapies may become more sophisticated, with improved vectors for precise and targeted delivery of therapeutic genes to specific cells.[33]

Continuous Manufacturing Technologies

Continuous manufacturing technologies could be further developed for injectables, enhancing efficiency, reducing costs, and allowing for more rapid scale-up in response to increased demand.[34]

3D Printing of Injectable Formulations

3D printing technology may enable the creation of personalized and complex injectable dosage forms, allowing for precise control over drug release profiles.[35]

Enhanced Stability and Long-Acting Formulations

Technologies that enhance the stability of injectables, extending their shelf life and reducing the need for cold chain storage, could become more prevalent. Advances in long-acting injectable formulations may lead to extended-release products, reducing the frequency of injections for certain therapies.[36]

Theragnostic Integrated Diagnosis and Treatment

Theranostic injectables, which combine diagnostic and therapeutic capabilities, could become more sophisticated. This integration allows for real-time monitoring of treatment effectiveness.[37]

Next-Generation Vaccines

Building on the success of mRNA-based COVID-19 vaccines, further research may lead to the development of mRNA vaccines for various diseases, as well as other innovative vaccine.[38]

Improved Patient Adherence Technologies

Development of smart injection devices that provide reminders, track adherence, and offer user-friendly interfaces to enhance patient engagement and compliance.[39]

These potential advancements are speculative and represent trends and areas of research interest. The actual trajectory of technological development in injectables will depend on ongoing scientific discoveries, regulatory considerations, and the evolving needs of patients and healthcare providers. Collaboration between researchers, pharmaceutical companies, and technology innovators will be essential in bringing these advancements to fruition.

Needle Guage

Needle gauge and length are critical considerations in the administration of injectable medications and play a crucial role in ensuring the effectiveness, safety, and comfort of the injection. The choice of needle gauge and length depends on various factors, including the type of medication, the route of administration, the patient's characteristics, and the intended therapeutic effect.[40]

GENERAL CONSIDERATIONS

Patient Comfort

Smaller gauge and shorter needles generally cause less discomfort for patients. Minimizing pain during injection contributes to patient compliance and overall satisfaction with the healthcare experience.[41]

Medication Viscosity

The viscosity of the medication influences the choice of needle gauge. More viscous medications may require larger gauge needles to facilitate smooth administration without causing excessive resistance.

Risk of Complications

Needle gauge and length choices impact the risk of complications, such as tissue trauma, bleeding, or nerve injury. Proper selection helps mitigate these risks and ensures safe and effective injections.

Injection Site

The injection site influences needle length selection. Different injection sites may require varying needle lengths to ensure proper medication delivery.[42]

The choice of needle gauge and length is a crucial aspect of injectable administration. Healthcare professionals carefully consider these factors to optimize patient comfort, minimize complications, and ensure the effective delivery of medications based on the specific characteristics of each injection.

ADVERSE EFFECTS

Injectable medications, while effective in treating various medical conditions, can be associated with potential adverse effects. The specific adverse effects depend on

factors such as the type of medication, the route of administration, the patient's individual response, and the dosage. Some potential adverse effects associated with injectables are enlisted in **Table No1**

Table No. 1: Potential adverse effects associated with injectables.

S.NO	ADVERSE EFFECTS	CONDITIONS
1.	Local Reactions at the Injection Site	Pain or Discomfort Swelling or Redness
2.	Allergic Reactions	Hypersensitivity Anaphylaxis[43]
3.	Systemic Effects	Flu-Like Symptoms Nausea and Vomiting[44]
4.	Hematologic Adverse Effects	Bleeding or Hematoma Thrombocytopenia[45]
5.	Neurological Effects	Nerve Damage
6.	Infections	Local Infections Systemic Infections
7.	Injection Site Reactions	Lipodystrophy Calcifications[46]
8.	Endocrine Effects	Hormonal Changes
9.	Cardiovascular Effects	Hypotension Arrhythmias
10.	Respiratory Effects	Dyspnoea[47]

It is crucial for healthcare providers to thoroughly assess and monitor patients receiving injectable medications, educate them about potential side effects, and promptly address any adverse reactions that may occur. Patient-specific factors, including medical history and individual response, should be considered when evaluating the potential risks and benefits of injectable therapies.

ISSUES FACED BY THE HEALTHCARE PROFESSIONALS

During the preparation and administration of injectables, healthcare professionals may encounter various issues that can impact the safety, efficacy, and overall success of the procedure. Some of them are enlisted below.

Medication Errors
Administering the wrong dosage of medication can lead to adverse effects or therapeutic failure.

Contamination
Using contaminated needles, syringes, or vials can introduce harmful microorganisms into the injection.[48]

Incorrect Route of Administration
Administering the medication via the wrong route (e.g., intramuscular instead of subcutaneous) may affect its absorption and therapeutic effectiveness.

Injection Site Issues
Choosing an incorrect injection site may lead to local tissue damage, reduced efficacy, or increased pain.

Needlestick Injuries
Inadequate precautions may result in accidental needlestick injuries, posing a risk of bloodborne infections to healthcare providers.[49]

Patient non-adherence
Patients may fail to comply with prescribed injection schedules due to a lack of understanding about the importance of the medication.[50]

Equipment Malfunctions
Compatibility issues between the medication and injection device can affect drug delivery.

Unexpected Allergic Reactions & Unforeseen Side Effects
Patients may experience unexpected allergic reactions, ranging from mild to severe. Some patients may develop side effects that were not anticipated based on the medication's known profile.[51]

Incorrect Reconstitution & Mixing Incompatibilities
Failing to reconstitute a medication properly or using the wrong diluent can compromise its stability and efficacy. Mixing medications that are incompatible can lead to chemical reactions and altered therapeutic effects.[52]

Documentation Issues
Failure to document the preparation and administration details accurately can lead to confusion, errors, or challenges in patient care continuity.

Patient Communication Challenges
Patients with limited health literacy may struggle to understand instructions or potential side effects.[53]

Incorrect Storage Conditions & Expired Medications
Failure to store injectables under the recommended conditions may compromise their stability and efficacy. Administering expired medications can be ineffective or pose risks to the patient.[54]

To address these issues, healthcare providers should prioritize ongoing training, adhere to best practices, and implement robust safety protocols. Open communication with patients, thorough documentation, and adherence to aseptic techniques are essential elements in minimizing risks associated with injectable preparations and administrations.

CONCLUSION

The realm of injectables stands at the forefront of medical innovation, showcasing a dynamic interplay of advanced technologies and therapeutic evolution. From

traditional formulations to cutting-edge gene therapies, injectables have transformed disease management across diverse medical domains. As evidenced by biodegradable microneedles, smart devices, and continuous manufacturing, the field continues to push boundaries, promising enhanced drug delivery precision and patient-centric experiences. Looking forward, personalized medicine, gene therapies, and secure supply chain technologies will likely define the future of injectables. Their pivotal role in responding to global health challenges, as demonstrated during pandemics, underscores the urgency of continued research and development. The journey from traditional injections to next-generation therapies reflects a relentless commitment to advancing healthcare, with injectables poised to be instrumental in shaping a healthier and more resilient world.

ACKNOWLEDGEMENT
The authors are grateful for RIPER –Autonomous.

CONFLICT OF INTEREST
None.

ABREVIATIONS
ETO: Ethylene Oxide, **ICH:** International Council for Harmonisation, **CFR:** Code Federal Regulations, **FDA:** Food and Drug Administration, **API:** Active Pharmaceutical ingredient **CAPA:** Corrective and Preventive Actions, **c GMP:** current Good Manufacturing practice, **PPE**: Personal Protective Equipment, **EMA:** European Medicines Agency, **VHP:** Vaporized Hydrogen Peroxide.

REFERENCES
1. Cascella M, Cascella A, Monaco F, Shariff MN. Envisioning gamification in anaesthesia, pain management, and critical care: basic principles, integration of artificial intelligence, and simulation strategies. Journal of Anaesthesia, Analgesia and Critical Care, 2023 Sep 11; 3(1): 33. DOI: 10.1186/s44158-023-00118-2.
2. Larrañeta E, Lutton RE, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Materials Science and Engineering: R: Reports, 2016 Jun 1; 104: 1-32. DOI: 10.1016/j.mser.2016.03.001.
3. Ghozali MT. Implementation of the IoT-based technology on patient medication adherence: A comprehensive bibliometric and systematic review. Journal of Information and Communication Technology, 2023 Oct 25; 22(4): 503-44.
4. Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current state of human gene therapy: approved products and vectors. Pharmaceuticals, 2023 Oct 5; 16(10): 1416. DOI: 10.3390/ph16101416.
5. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon, 2024 Feb 15.
6. Kumar R, Rana A. Basic concepts of sterilization techniques. Research Journal of Pharmacology and Pharmacodynamics, 2021; 13(4): 155-61. DOI: Kumar R, Rana A. Basic concepts of sterilization techniques. Research Journal of Pharmacology and Pharmacodynamics, 2021; 13(4): 155-61.
7. Rogers WJ. Steam and dry heat sterilization of biomaterials and medical devices. InSterilisation of Biomaterials and Medical Devices, 2012 Jan 1: 20-55. Woodhead Publishing. DOI: 10.1533/9780857096265.20
8. Rutala WA, Weber DJ. Sterilization of 20 billion medical devices by ethylene oxide (ETO): Consequences of ETO closures and alternative sterilization technologies/solutions. American Journal of Infection Control, 2023 Nov 1; 51(11): A82-95.DOI: 10.1016/j.ajic.2006.10.014
9. Tanzini A, Ruggeri M, Bianchi E, Valentino C, Vigani B, Ferrari F, Rossi S, Giberti H, Sandri G. Robotics and Aseptic Processing in View of Regulatory Requirements. Pharmaceutics, 2023 May 24; 15(6): 1581.DOI: 10.3390/pharmaceutics15061581
10. Jatta M, Kiefer C, Patolia H, Pan J, Harb C, Marr LC, Baffoe-Bonnie A. N95 reprocessing by low temperature sterilization with 59% vaporized hydrogen peroxide during the 2020 COVID-19 pandemic. American journal of infection control, 2021 Jan 1; 49(1): 8-14.DOI: 10.1016/j.ajic.2020.06.194
11. Bykowski T, Stevenson B. Aseptic technique. Current protocols in microbiology, 2008 Nov; 11(1): A-4D. DOI: 10.1002/9780471729259.mca04ds11
12. Menges L, Giesen J, Yilmaz K, Mergia E, Füchtbauer A, Füchtbauer EM, Koesling D, Russwurm M. It takes two to tango: cardiac fibroblast-derived NO-induced cGMP enters cardiac myocytes and increases cAMP by inhibiting PDE3. Communications Biology, 2023 May 10; 6(1): 504. DOI: 10.1038/s42003-023-04880-5
13. Shukla SS, Pandey RK, Gidwani B, Kalyani G. Process Validation and Its Types. In Pharmaceutical Calibration, Validation and Qualification: A Comprehensive Approach, 2023 Feb 15; 121-133. DOI: 10.1007/978-981-19-9002-1_10
14. Campbell NH, Gregory IM, Acheson MJ, Ilangovan HS, Ranganathan S. Benchmark Problem for Autonomous Urban Air Mobility. InAIAA SCITECH 2024 Forum, 2024; 0718. DOI: 10.2514/6.2024-0718
15. Janssen R, Cuypers L, Laenen L, Keyaerts E, Beuselinck K, Janssenswillen S, Slechten B, Bode J, Wollants E, Van Laethem K, Rector A. Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference

Centre. Virology journal, 2024 Feb 10; 21(1): 40. DOI: 10.1186/s12985-024-02308-y
16. Vidas-Guscic N, Van Rijswijk J, Van Audekerke J, Jeurissen B, Nnah I, Tang H, Munoz-Sanjuan I, Pustina D, Cachope R, Van der Linden A, Bertoglio D. Diffusion MRI marks progressive alterations in fiber integrity in the zQ175DN mouse model of Huntington's disease. Neurobiology of Disease, 2024 Feb 15: 106438. DOI:10.1016/j.nbd.2024.106438
17. Dash AK. Quality Assurances of Dosage Forms. In Pharmaceutics, 2024 Jan 1; 471-484. Academic Press. DOI: 10.1016/B978-0-323-99796-6.00016-3
18. Lange R, Schnor T. Product Quality, Quality Control and Validation. InPractical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, 2023 Jun 16; 767-783. Cham: Springer International Publishing. DOI:10.1007/978-3-031-20298-8_32
19. Mencke N, Blazejak K, Petry G, Hamburg H, Ringeisen H, Knoppe TN, Viljoen A, Smith A, Spruill J. Immediate and long-term efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel applied as a single application to cats artificially infested with the cat flea Ctenocephalides felis. Current Research in Parasitology & Vector-Borne Diseases, 2023 May 30: 100122. DOI: 10.1016/j.crpvbd.2023.100122
20. Lyndon A, Davis DA, Sharma AE, Scott KA. Emotional safety is patient safety. BMJ Quality & Safety, 2023 Jul 1; 32(7): 369-72. 10.1136/bmjqs-2022-015573
21. Tubic-Grozdanis M, Krämer I. Parenteral. InPractical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, 2023 Jun 16; 473-519. Cham: Springer International Publishing. DOI: 10.1007/s13346-022-01223-5
22. Kumar H, Yadav S. Additive and Good Manufacturing Practices in Conformity Assessment. In Handbook of Quality System, Accreditation and Conformity Assessment, 2024 Jan 8; 1-18. Singapore: Springer Nature Singapore. DOI: 10.1007/978-981-99-4637-2_53-1
23. Mays A, Ayers P, Monczka J, Cober MP. Safety in parenteral nutrition compounding. Nutrition in Clinical Practice, 2023 Dec; 38(6): 1253-62. DOI: 10.1002/ncp.11064
24. Sharma A, Gamta V, Luthra G. Regulatory Compliance in the United States: A Comprehensive Analysis of USFDA Guidelines and Implementation Strategies. Journal of Pharmaceutical Research International, 2023 Jul 7; 35(17): 41-50. Doi: 10.9734/jpri/2023/v35i177389
25. ICH. ICH Official web site: ICH [Internet]. Ich.org. 2019. Available from: https://www.ich.org/page/ich-guidelines
26. Makurvet FD. Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery, 2021 Mar 1; 9: 100075. Doi:10.1016/j.medidd.2020.100075
27. Wang X, Li R, Zhao H. Enhancing angiogenesis: Innovative drug delivery systems to facilitate diabetic wound healing. Biomedicine & Pharmacotherapy, 2024 Jan 1; 170: 116035. Doi: 10.1016/j.biopha.2023.116035
28. Srivastava S, Jayaswal N, Kumar S, Sharma PK, Behl T, Khalid A, Mohan S, Najmi A, Zoghebi K, Alhazmi HA. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management. Cellular Signalling, 2024 Jan 1; 113: 110932. Doi:10.1016/j.cellsig.2023.110932
29. Crommelin DJ, Mastrobattista E, Hawe A, Hoogendoorn KH, Jiskoot W. Shifting paradigms revisited: biotechnology and the pharmaceutical sciences. Journal of Pharmaceutical Sciences, 2020 Jan 1; 109(1): 30-43. Doi: 10.1016/j.xphs.2019.08.010
30. Kumraj G, Pathak S, Shah S, Majumder P, Jain J, Bhati D, Hanif S, Mukherjee S, Ahmed S. Capacity building for vaccine manufacturing across developing countries: the way forward. Human Vaccines & Immunotherapeutics, 2022 Jan 31; 18(1): 2020529. Doi: 10.1080/21645515.2021.2020529
31. Kana BD, Arbuthnot P, Botwe BK, Choonara YE, Hassan F, Louzir H, Matsoso P, Moore PL, Muhairwe A, Naidoo K, Ndomondo-Sigonda M. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa. The Lancet Infectious Diseases, 2023 Jun 5. doi: 10.1016/S1473-3099(22)00878-7
32. Fauci AS, Folkers GK. Pandemic preparedness and response: lessons from COVID-19. The Journal of Infectious Diseases, 2023 Aug 15; 228(4): 422-5. Doi: 10.1093/infdis/jiad095
33. Sanchez-Moreno P, Ortega-Vinuesa JL, Peula-Garcia JM, Marchal JA, Boulaiz H. Smart drug-delivery systems for cancer nanotherapy. Current drug targets, 2018 Mar 1; 19(4): 339-59. Doi: 10.2174/1389450117666160527142544
34. Burcham CL, Florence AJ, Johnson MD. Continuous manufacturing in pharmaceutical process development and manufacturing. Annual review of chemical and biomolecular engineering, 2018 Jun 7; 9: 253-81.
35. Eugster R, Ganguin AA, Seidi A, Aleandri S, Luciani P. 3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases. Drug delivery and translational research, 2023 Nov 25: 1-5. Doi: 10.1007/s13346-023-01472-y
36. Xiong Y, Wang J, Zhou X, Li X. The Development of a Stable Peptide-Loaded Long-Acting Injection Formulation through a Comprehensive Understanding of Peptide Degradation Mechanisms:

A QbD-Based Approach. Pharmaceutics, 2024 Feb 13; 16(2): 266. Doi:10.3390/pharmaceutics16020266

37. Fang C, Zhang M. Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine. Journal of controlled release: official journal of the Controlled Release Society, 2010 Aug 8; 146(1): 2. doi: 10.1016/j.jconrel.2010.05.013
38. Li X, Qi J, Wang J, Hu W, Zhou W, Wang Y, Li T. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape. Theranostics, 2024; 14(2): 738. doi: 10.7150/thno.84291
39. Sharma V, Feldman M, Sharma R. Telehealth technologies in diabetes self-management and education. Journal of Diabetes Science and Technology, 2024 Jan; 18(1): 148-58. Doi: 10.1177/1932296822109307
40. Valros A, Norring M, Ahlqvist K, Bergqvist T, Ceron JJ, Lopez-Arjona M, Heinonen M. Effects of repeated intramuscular injections on sow behaviour reactions and stress-related saliva biomarkers–A pilot study. Applied Animal Behaviour Science, 2024 Feb 1; 271: 106173. doi: 10.1016/j.applanim.2024.106173
41. Bowers B, Pollock K, Wilkerson I, Massou E, Brimicombe J, Barclay S. Administering injectable medications prescribed in the anticipation of the end of life in the community: A mixed-methods observational study. International Journal of Nursing Studies, 2024 Feb 29: 104734. doi: 10.1016/j.ijnurstu.2024.104734
42. Rho NK, Kim HJ, Kim HS, Lee W. Needle-Free Jet Injection of Poly-(Lactic Acid) for Atrophic Acne Scars: Literature Review and Report of Clinical Cases. Journal of Clinical Medicine, 2024 Jan 13; 13(2): 440. doi: 10.3390/jcm13020440
43. Kaplan B, Coscia G, Fishbein JS, Innamorato A, Ali A, Farzan S. Gastrointestinal reflux contributes to laryngopharyngeal symptoms that mimic anaphylaxis: COVID-19 vaccination experience. Journal of Allergy and Clinical Immunology: Global, 2024 Feb 1; 3(1): 100176. Doi: 10.1016/j.jacig.2023.100176
44. Wu Q, Zhang P, Zhou G, Fu Q, Bai R, Ding H, Meng F, Xu X, Chen M. Impact of SARS-CoV-2 Vaccination or Infection on the Safety and Efficacy of Aesthetic Injections: A Systematic Review. Aesthetic Plastic Surgery, 2024 Feb 1: 1-0. Doi: 10.1007/s00266-023-03769-2
45. Shaikh SM, Toshniwal S, Wanjari A, Acharya S, Kumar S, Toshniwal SS. Anti-Tubercular-Therapy-Induced Severe Thrombocytopenia Presenting as a Vocal Cord Bleed With Massive Hemoptysis Causing Mortality: A Catastrophic Combination. Cureus, 2024 Feb 7; 16(2). Doi: 10.7759/cureus.53752
46. Bartalucci C, Baldi F, Ricci E, Orofino G, Menzaghi B, Ferrara S, Pellicano GF, Squillace N, Sarchi E, Pontali E, Cenderello G. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?. AIDS, 2024 Mar 1; 38(3): 430-4. Doi: 10.1097/QAD.0000000000003766
47. Lee DJ, Kuerec AH, Maier AB. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. The Lancet Healthy Longevity, 2024 Feb 1; 5(2): e152-62. Doi: 10.1016/S2666-7568(23)00258-1
48. Memon SI, Khan SS, Sharif Z, Younus S, Manghrio UI. Quality Assurance in Safe Handling of Hazardous Drugs Among Healthcare Workers in KSA: A Scoping Review: Safe Handling of Hazardous Drugs Among Healthcare Workers. Pakistan BioMedical Journal, 2024 Feb 29.doi: 10.54393/pbmj.v7i02.1006
49. Gupta S, Ramteke H, Gupta S, Gupta S, Gupta KS, Gupta SS. Are People With Type 1 Diabetes Mellitus Appropriately Following Insulin Injection Technique Practices: A Review of Literature. Cureus, 2024 Jan 1; 16(1). Doi: 10.7759/cureus.51494
50. Zhang J, Zhang Y, Yin Y, Feng Y, Zhang R, Meng H, Wang J. 'Fear, uncertain, tired…...'psychological distress among pulmonary hypertension patients: a qualitative interview study. BMC psychiatry, 2024 Feb 5; 24(1): 100.
51. Elkateb S, Métwalli A, Shendy A, Abu-Elanien AE. Machine learning and IoT–Based predictive maintenance approach for industrial applications. Alexandria Engineering Journal, 2024 Feb 1; 88: 298-309. Doi:10.1016/j.aej.2023.12.065
52. Gostyńska A, Przybylski T, Ogrodowczyk M. Y-Site Compatibility Studies of Parenteral Nutrition and Other Intravenous Medications in Neonatal and Pediatric Patients: A Review of the Literature Evidence. Pharmaceutics, 2024 Feb 12; 16(2): 264. Doi: 10.3390/pharmaceutics16020264
53. Weber TM, Sinojia S, Shao C, Chu DI, Kinard BE. What Is Health Literacy Among Orthognathic Surgery Patients?. Journal of Oral and Maxillofacial Surgery, 2024 Jan 6. Doi: 10.1016/j.joms.2024.01.004
54. Wang H, Ke X, Tang S, Ren K, Chen Q, Li C, Ran W, Ding C, Yang J, Luo J, Li J. Natural Underwater Bioadhesive Offering Cohesion Modulation via Hydrogen Bond Disruptor: A Highly Injectable and in Vivo Stable Remedy for Gastric Ulcer Resolution. Small, 2024 Jan 8: 2307628. Doi: 10.1002/smll.202307628